Valuation: Polaris Group

Market Cap 718.19Cr 22Cr 20Cr 18Cr 16Cr 31Cr 2.09TCr 31Cr 218.73Cr 87Cr 1.1TCr 83Cr 81Cr 3.45TCr P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 769.88Cr 24Cr 21Cr 19Cr 18Cr 33Cr 2.24TCr 34Cr 234.47Cr 93Cr 1.17TCr 89Cr 87Cr 3.7TCr EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
33.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.59%
1 week-4.04%
Current month-13.45%
1 month-19.09%
3 months-33.11%
6 months-54.00%
Current year-74.19%
1 week 15.3
Extreme 15.3
16.15
1 month 15.3
Extreme 15.3
18.35
Current year 15.3
Extreme 15.3
69.2
1 year 15.3
Extreme 15.3
70.64
3 years 15.3
Extreme 15.3
157.65
5 years 15.3
Extreme 15.3
446.58
10 years 15.3
Extreme 15.3
446.58
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Chairman 64 24/11/2014
Director/Board Member - 25/02/2020
Director/Board Member - 03/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.59%-4.04%-77.80%-89.15% 22Cr
+2.41%+0.29%+39.41%+72.14% 6.47TCr
-0.15%+7.50%+11.42%+71.27% 5.48TCr
+0.57%+4.60%+7.71%+90.93% 5.35TCr
+0.37%+4.67%+26.68%+49.64% 4.6TCr
-1.21%+2.32%+21.50%+118.33% 4.29TCr
-0.37%+5.07%+243.23%+789.58% 4.01TCr
+0.05%+0.21%+18.06%+48.50% 3.35TCr
+1.19%-4.98%+26.31%-0.76% 2.4TCr
-0.38%+5.68%+38.39%+28.35% 2.37TCr
Average +0.09%+1.77%+35.49%+117.88% 3.83TCr
Weighted average by Cap. +0.39%+2.73%+45.95%+142.70%

Financials

2024 2025
Net sales 11Cr 32.83L 29.31L 27.08L 24.54L 45.91L 31Cr 46.67L 3.26Cr 1.29Cr 16Cr 1.23Cr 1.21Cr 51Cr 4.06Cr 12.46L 11.12L 10.28L 9L 17.42L 12Cr 17.71L 1.24Cr 48.96L 6.2Cr 46.75L 45.75L 20Cr
Net income -250.26Cr -7.68Cr -6.86Cr -6.33Cr -5.74Cr -11Cr -728.84Cr -11Cr -76Cr -30Cr -381.87Cr -29Cr -28Cr -1.2TCr -392.71Cr -12Cr -11Cr -9.94Cr -9.01Cr -17Cr -1.14TCr -17Cr -119.6Cr -47Cr -599.22Cr -45Cr -44Cr -1.89TCr
Net Debt 91.92L 3L 3L 2L 2L 4L 2.68Cr 4L 27.99L 11.08L 1.4Cr 10.58L 10.36L 4.42Cr 52Cr 1.59Cr 1.42Cr 1.31Cr 1.19Cr 2.22Cr 150.53Cr 2.25Cr 16Cr 6.23Cr 79Cr 5.95Cr 5.82Cr 248.66Cr
Projected Income Statement - Annual - Polaris Group
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
22/26/22 NT$15.45 -1.59% 2,43,873
21/26/21 NT$15.70 +1.29% 2,25,085
20/26/20 NT$15.50 -0.32% 4,06,414
19/26/19 NT$15.55 -3.42% 3,52,353
16/26/16 NT$16.10 +1.26% 2,48,583
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock